Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 18;16(1):142-149.
doi: 10.1515/biol-2021-0017. eCollection 2021.

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Snezana Mugosa  1   2 , Zoran Todorovic  3 , Jelena Cukic  4 , Majda Sahman-Zaimovic  1   2 , Natasa Djordjevic  5
Affiliations

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Snezana Mugosa et al. Open Life Sci. .

Abstract

Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene. Thus, the aim of this study was to investigate the effect of ABCB1 genetic polymorphism on clopidogrel efficacy and safety and to determine the frequency distribution of its most common single nucleotide polymorphisms (SNPs) in 106 Montenegrin cardiology patients. Clopidogrel efficacy and safety were followed up during 1 year after hospitalization, with the lack of efficacy and adverse drug reactions observed in 11 (10.4%) and 8 patients (7.5%), respectively. Genotyping for ABCB1 SNPs rs1128503 (1236C > T), rs2032582 (2677G > A/T), and rs1045642 (3435C > T) was performed by the real-time PCR method, and the variant alleles were detected with the frequencies of 42.9, 44.8, and 52.8%, respectively. No significant association was observed between any of the examined genotypes and clopidogrel efficacy (p = 0.253) or safety (p = 0.424). Due to small sample size, co-treatment with other drugs, and other genetic factors not taken into account, we believe the absence of correlation between ABCB1 genotypes and indicators of clopidogrel efficacy and safety in this study should be apprehended conditionally, and that larger and better-controlled studies are warranted.

Keywords: ABCB1; P-glycoprotein; clopidogrel; single nucleotide polymorphism.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors state no conflict of interest.

Figures

Figure A1
Figure A1
Questions included in patient interview 1 year after hospital discharge.
Figure A2
Figure A2
Patient questionnaire during hospitalization.
See this image and copyright information in PMC

References

    1. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4:252–61. - PubMed
    2. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4:252–61. - PubMed
    1. Zhang Q, Wang C, Zheng M, Li Y, Li J, Zhang L, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis. 2015;39:13–22. - PubMed
    2. Zhang Q, Wang C, Zheng M, Li Y, Li J, Zhang L. et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis. 2015;39:13–22. - PubMed
    1. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101:960–6. - PubMed
    2. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101:960–6. - PubMed
    1. Mugoša S, Djordjević N, Bukumirić Z, Djukanović N, Cukić J, Radosavljević I, et al. Predict score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. Clin Exp Pharmacol Physiol. 2016;43:379–81. - PubMed
    2. Mugoša S, Djordjević N, Bukumirić Z, Djukanović N, Cukić J, Radosavljević I. et al. Predict score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. Clin Exp Pharmacol Physiol. 2016;43:379–81. - PubMed
    1. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21–30. - PubMed
    2. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA. et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21–30. - PubMed

LinkOut - more resources